Determinants of Long‐Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis
American Journal of Hematology · 2026
DOI: 10.1002/ajh.70371 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Maximilian J Steinhardt und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Melphalan, Immunoglobulin Light-chain Amyloidosis, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
High dose melphalan (HDM) with autologous stem cell transplant is an established treatment for systemic light chain amyloidosis, but its incremental benefit in the era of effective standard intensity therapy is unknown. We retrospectively analyzed 475 transplant‐eligible patients who completed standard intensity treatment with or without HDM within 12 months at six centers in Europe and the United States between 2010 and 2024 to evaluate outcomes by baseline risk factors, hematologic response, and receipt of HDM. Death was an equally competing risk after the 12‐month landmark chosen to address early non‐proportional hazards and to ensure completion of first‐line therapy. BMPC > 20% was associated with inferior outcomes (HR 1.7), and gain/amp 1q with shorter TTP (HR 2.15), whereas other high‐risk FISH abnormalities were not. In multivariable models, VGPR/CR after standard intensity therapy was associated with longer TTP (HR 0.49/0.29), while gain/amp 1q remained independently associated with shorter TTP (HR 2.18). Receipt of daratumumab and HDM were associated with longer TTP (HR 0.44/0.61). HDM benefited patients who had not achieved CR after standard intensity therapy (mTTP 21.0 vs. 5.7 months without HDM), whereas patients already in CR did not benefit. Higher BMPC at diagnosis was associated with earlier progression in patients not receiving HDM (HR 1.9 for 5%–20% and 4.09 for > 20%), a risk attenuated in the HDM cohort. Gain/amp 1q remained associated with shorter TTP regardless of HDM exposure. These findings support a selective role for HDM, primarily benefiting patients with residual disease after standard intensity therapy or higher BMPC burden at diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
- Interdisciplinary Amyloidosis Center, University Hospital Würzburg, Würzburg, Germany.
- Department of Internal Medicine V, Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany.
- Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.
- West German Amyloidosis Center, University Hospital Essen, Essen, Germany.
ORCID-Profile: Maximilian J Steinhardt, Ute Hegenbart, Murielle Roussel, Max J Rieger, Vladimir Cejka, Morie Gertz, Eli Muchtar
Zitieren
APA
Steinhardt, M. J., Hegenbart, U., Hellou, T., Oubari, S., Roussel, M., Schwotzer, R., Buadi, F., Dingli, D., Binder, M., Kourelis, T., Zanwar, S. S., Rieger, M. J., Morbach, C., Cejka, V., Gerber, B., Störk, S., Einsele, H., Kumar, S., Gertz, M., …, & Schönland, S. (2026). Determinants of Long‐Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis. American Journal of Hematology. https://doi.org/10.1002/ajh.70371
Vancouver
Steinhardt MJ, Hegenbart U, Hellou T, Oubari S, Roussel M, Schwotzer R, et al. Determinants of Long‐Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis. American Journal of Hematology. 2026. doi:10.1002/ajh.70371
BibTeX
@article{Steinhardt2026,
author = {Steinhardt, Maximilian J and Hegenbart, Ute and Hellou, Tamer and Oubari, Sara and Roussel, Murielle and Schwotzer, Rahel and Buadi, Francis and Dingli, David and Binder, Moritz and Kourelis, Taxiarchis and Zanwar, Saurabh S and Rieger, Max J and Morbach, Caroline and Cejka, Vladimir and Gerber, Bernhard and Störk, Stefan and Einsele, Hermann and Kumar, Shaji and Gertz, Morie and Carpinteiro, Alexander and Kortum, K Martin and Muchtar, Eli and Dispenzieri, Angela and Schönland, Stefan},
title = {Determinants of Long‐Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis},
journal = {American Journal of Hematology},
year = {2026},
doi = {10.1002/ajh.70371}
}
EUVIMED